Literaturverzeichnis zum Titelthema „Neues aus der Diabetologie“
Bayerisches Ärzteblatt 4/2009, Seite 152 ff.
Professor Dr. Petra-Maria Schumm-Draeger und Dr. Thorsten Siegmund
Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 2006; 57: 265–81.
Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypo- glycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073–84.
Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bed- time neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 dia- betes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952–9.
Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in pa- tients with type 2 diabetes. N Engl J Med. 2003; 348(5):383-93.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358(6): 580–91.
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes Study Group (VADT), New Engl J Med 2009; 360: 1-11.
Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in pa- tients with type 2 diabetes. Diabetes Obes Metab 2005; 7: 56–64.
Hauner H. The costs of diabetes mellitus and its complications in Germany. Dtsch Med Wochenschr 2006; 131(Suppl 8): S240–2.
Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, ran- domized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269–74.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA,10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008; 351: 1-13.
Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC, for the 4-T Study Group. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. N Engl J Med 2007; 357: 16–30.
Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254–9.
Kendall DM, Bergenstal RM. Comprehensive management of patients with type 2 diabetes: es- tablishing priorities of care. Am J Manag Care. 2001; 7(10 Suppl):S327-43.
Liebl A, Neiss A, Spannheimer A, Reitberger U, Wieseler B, Stammer H, Goertz A. Complica- tions, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany – results from the CODE-2 study. Exp Clin Endocrinol Diabetes 2002; 110: 10–6.
Seite 1 von 3
Matthaei S, Haering HU. Praxis Leitlinien der Deutschen Diabetes Gesellschaft. Bahnadlung des Diabetes mellitus Typ 2. Diabetologie 2008; 3(Suppl 2): S157–161.
Matthaei S et al. Medikamentöse antihyperglykämische Therapie des Typ 2 Diabetes mellitus.
Diabetologie. 2009; 4:32-64. http://www.deutsche-
diabetesgesellschaft.de/redaktion/mitteilungen/leitlinien/EBL_Dm_Typ2_Update_2008.pdf.
Monnier L, Colette C, Dunseath GJ, Owens DR. The Loss of Postprandial Glycemic Control Pre- cedes Stepwise Deterioration of Fasting With Worsening Diabetes. Diabetes Care 2007; 30:
263–269.
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose in- crements to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with in- creasing levels of HbA(1c). Diabetes Care 2003; 26: 881–5.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European As- sociation for the Study of Diabetes. Diabetes Care. 2009; 32(1):193-203.
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular dis- ease in patients with type 1 diabetes. N Engl J Med 2005; 22:2643-53.
Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A; INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260–5.
Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–6.
Ritzel RA, Veldhuis JD, Butler PC. Glucose stimulates pulsatile insulin secretion from human pancreatic islets by increasing secretory burst mass: dose-response relationships. J Clin En- docrinol Metab 2003; 88: 742–7.
Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglyce- mia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH in- sulin in type 2 diabetes. Diabetes Care 2005; 28: 950–5.
Shah V, Pratley RE. The DREAM Trial: Using Ramipril and Rosiglitazone to Prevent Diabetes.
Curr Diab Rep 2007; 7: 53–55.
Siegmund T, Weber S, Blankenfeld H, Oeffner A, Schumm-Draeger PM. Comparison of insulin glargine versus NPH insulin in people with Type 2 Diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes 2007; 115: 349–353.
Siegmund T. Indikationen zur Insulintherapie bei Typ-2-Diabetes. Wahl des Therapie-Regimes nach individuellen Kriterien. Notfall & Hausarztmedizin 2007; 33 (3): 140–144
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008 358: 2545–59.
Seite 2 von 3
Seite 3 von 3
The Advance Collaborative Group. Intensive Bolld Glucose Control and vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008; 358: 2560–72.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet.
1998; 352(9131):854-65.
U.K. prospective diabetes study 16. Overview over 6 years therapy of type II diabetes: a progres- sive disease. Diabetes 1995; 44: 1249–58.
